Mapi Pharma is a clinical-stage, fully integrated biopharmaceutical company developing high barrier-to-entry, high added-value lifecycle management (LCM) pharmaceuticals and complex active pharmaceutical ingredients (APIs) and formulations. Its lead product is a Glatiramer Acetate (Copaxone®) Depot long-acting injection administered once every four weeks, which is in final preparations for a phase III clinical trial. The company plans to expand its pipeline to additional 505(b)(2) and Depot innovative and QQ products beyond the GA Depot. Mapi is built on chemical and pharmaceutical R&D capabilities, with R&D facilities in Israel and China and an API production facility in the Neot-Hovav Eco Industrial Park in Israel. The company holds a strong IP position and has filed numerous patent applications for APIs and formulations. The recent equity investment will support Mapi’s future development and pipeline expansion. Mapi Pharma Ltd. is a clinical-stage biopharmaceutical company developing long-acting depot injections for multiple sclerosis. Its lead product, Glatiramer Acetate (Copaxone®) Depot (GA Depot), is a once-every-four-weeks intramuscular injection and a life‑cycle management (LCM) formulation of Copaxone®. The company recently completed a Phase II open-label, two-arm, multicenter study evaluating safety, tolerability, and efficacy of once-a-month 80mg or 40mg GA in relapsing-remitting MS patients. Mapi received $10m in funding from aMoon Fund to support development and enable initiation of a Phase III trial for GA Depot. Led by Chairman and CEO Ehud Marom, the company focuses on LCM products and complex generics and intends to advance additional depot long-acting injections in its pipeline. Mapi maintains R&D facilities in Israel and China and an API production facility in the Neot-Hovav Eco Industrial Park south of Beersheba, Israel. Mapi Pharma is a development-stage pharmaceutical company based in Ness Ziona, Israel. It is developing the GA Depot, a once-every-four-weeks glatiramer acetate injection for the treatment of multiple sclerosis. The GA Depot was in Phase II at the time of the report. The company intends to use the funds to advance the product to the initiation of the single pivotal Phase III trial needed for registration. The company is led by chairman and CEO Ehud Marom. The recent financing was announced to support progression of the GA Depot clinical program.

Total raised

$30M

Funding rounds

3

Latest round

Equity

Latest activity

Nov 2018